导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.60% | 2362/4773 |
| 近一周 | -2.93% | 3394/5462 |
| 近一月 | -7.50% | 3846/5421 |
| 近一季 | -13.64% | 4047/5209 |
| 近半年 | -2.16% | 1801/4920 |
| 近一年 | 1.72% | 2282/4366 |
| 近两年 | 57.63% | 1272/2954 |
| 近三年 | 30.59% | 1033/2253 |
| 成立以来 | 76.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.69% 2431/4961 |
20.67% 1213/5312 |
- - |
- - |
| 2025 | 25.51% 1706/4813 |
-0.71% 2371/3635 |
-0.66% 2994/4076 |
29.79% 1205/4524 |
-1.96% 3048/4813 |
| 2024 | 12.91% 1201/3463 |
0.43% 977/2808 |
-3.18% 1315/3014 |
19.75% 812/3129 |
-3.03% 2238/3463 |
| 2023 | -14.85% 1624/2656 |
4.30% 990/2280 |
-5.88% 1551/2385 |
-7.07% 1522/2515 |
-6.67% 1863/2655 |
| 2022 | -23.22% 1115/2207 |
-17.62% 1230/1919 |
8.66% 341/2016 |
-15.62% 1323/2113 |
1.66% 1184/2208 |
| 2021 | 1.27% 681/1822 |
-3.91% 834/1255 |
10.46% 461/1330 |
-7.33% 1044/1466 |
2.96% 491/1822 |
| 2020 | 49.93% 174/1250 |
-4.73% 381/1028 |
20.88% 257/1067 |
10.81% 512/1164 |
17.49% 122/1184 |
| 2019 | - - |
- - |
-2.21% 341/788 |
4.55% 194/850 |
11.16% 77/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 方正富邦深证100ETF联接A VS. 长安沪深300非周期A(740101) |